Your browser doesn't support javascript.
loading
Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.
Prasad, Abhishek N; Agans, Krystle N; Geisbert, Joan B; Borisevich, Viktoriya; Deer, Daniel J; Dobias, Natalie S; Comer, Jason E; Woolsey, Courtney; Fenton, Karla A; Geisbert, Thomas W; Cross, Robert W.
  • Prasad AN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Agans KN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Geisbert JB; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Borisevich V; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Deer DJ; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Dobias NS; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Comer JE; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Woolsey C; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Fenton KA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Cross RW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
J Infect Dis ; 228(Suppl 7): S571-S581, 2023 11 13.
Article en En | MEDLINE | ID: mdl-37348509
ABSTRACT

BACKGROUND:

The primary route of infection by Ebola virus (EBOV) is through contact of mucosal surfaces. Few studies have explored infection of nonhuman primates (NHPs) via the oral mucosa, which is a probable portal of natural infection in humans.

METHODS:

To further characterize the pathogenesis of EBOV infection via the oral exposure route, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona.

RESULTS:

Infection with 100 or 50 PFU of EBOV Makona via the oral route resulted in 50% and 83% lethality, respectively. Animals that progressed to fatal disease exhibited lymphopenia, marked coagulopathy, high viral loads, and increased levels of serum markers of inflammation and hepatic/renal injury. Survival in these cohorts was associated with milder fluctuations in leukocyte populations, lack of coagulopathy, and reduced or absent serum markers of inflammation and/or hepatic/renal function. Surprisingly, 2 surviving animals from the 100- and 50-PFU cohorts developed transient low-level viremia in the absence of other clinical signs of disease. Conversely, all animals in the 10 PFU cohort remained disease free and survived to the study end point.

CONCLUSIONS:

Our observations highlight the susceptibility of NHPs, and by extension, likely humans, to relatively low doses of EBOV via the oral route.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Ebolavirus Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Ebolavirus Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article